Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Melco Partners With Marriott To Develop W Hotel In Macau

Melco Resorts & Entertainment Ltd (NASDAQ:MLCO) has entered into a strategic partnership with Marriott International Inc (NASDAQ:MAR) to bring the W Hotels Worldwide…
byShivani Kumaresan
December 22, 2021
1 minute read
Total
0
Shares
0
0
0
0
0
0
  • Melco Resorts & Entertainment Ltd (NASDAQ:MLCO) has entered into a strategic partnership with Marriott International Inc (NASDAQ:MAR) to bring the W Hotels Worldwide brand to Studio City Phase 2 in Macau.
  • W Macau – Studio City is scheduled to be open together with Studio City Phase 2 in December 2022.
  • The hotel will feature 557 guestrooms, including 127 suites and wellness facilities, a spa, fitness center, and indoor swimming pool.
  • Studio City’s hospitality offerings include indoor & outdoor water parks, a six-screen Cineplex, residency shows, and state-of-the-art MICE space.
  • Price Action: MLCO shares closed higher by 9.99% at $9.91 on Tuesday.
 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Reported Late Thursday, Theratechnologies Announces Update From Ongoing TH1902 Study; Decided To Pause The Enrollment Of Patients In Its Phase 1 Clinical Trial Of Th1902; Plans To Submit An Amendment To Its Protocol To The U.S. FDA For Approval

By Benzinga Newsdesk
Today, 10:09 PM
Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX:TH) (NASDAQ:THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today

THTX

Read More

Satsuma Pharmaceuticals Says Analysis Of Results From Recently-Completed Summit Phase 3 Efficacy Trial Of Sts101 For The Acute Treatment Of Migraine Shows Differentiating Robust, Sustained Antimigraine Effects On Clinically Important Secondary Endpoint…

By Benzinga Newsdesk
Today, 10:09 PM
Satsuma Pharmaceuticals Provides STS101 Development Program and Corporate Update Further analysis of results from recently-completed SUMMIT Phase 3 efficacy trial of STS101 for the acute treatment of migraine shows

STSA